Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

U.S. CDC signs off on Moderna, J&J COVID-19 vaccine boosters, mix-and-match shots

CoronavirusOct 22, 2021 08:35
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: A general view of the U.S. Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia September 30, 2014. REUTERS/Tami Chappell

By Manas Mishra and Julie Steenhuysen

(Reuters) - The U.S. Centers for Disease Control and Prevention (CDC) on Thursday recommended the COVID-19 vaccine boosters for recipients of the Moderna (NASDAQ:MRNA) Inc and Johnson & Johnson (NYSE:JNJ) shots, and said Americans can choose a different shot from their original inoculation as a booster.

CDC director Rochelle Walensky signed off on the recommendations late on Thursday, aligning the agency with the U.S. Food and Drug Administration's authorization https://www.reuters.com/world/us/us-fda-clears-moderna-jj-boosters-backs-mix-and-match-strategy-2021-10-20 on Wednesday for the additional boosters and "mix-and-match" dosing.

Walensky said that vaccines authorized in the United States "are all highly effective in reducing the risk of severe disease, hospitalization, and death, even in the midst of the widely circulating Delta variant" of the coronavirus.

A panel of advisers to the CDC had unanimously backed COVID-19 vaccine boosters earlier on Thursday.

Still, health officials and public health experts said the booster rollout could be confusing.

The panel struggled with trying to make the language of its recommendations as clear as possible, and also offer flexibility for patients to get a vaccine of their choice.

"A really important aspect of all of this is being clear and not dancing on the head of a pin, so that we don't further confuse the American people," said Dr. Beth Bell, a panel member and clinical professor in the department of global health at the University of Washington in Seattle.

The recommendations also open the door for recipients of the one-shot J&J vaccine to get a dose of the Pfizer or Moderna vaccines that have been shown to afford greater protection in a variety of studies.

Although these vaccines have been highly effective in preventing serious illness and death, some government scientists have suggested that boosters are needed to keep immunity high, especially as the extremely contagious Delta variant can cause breakthrough infections among some who are fully vaccinated.

ACIP voted to recommend booster doses for everyone 18 and older who received a first dose of Johnson & Johnson's vaccine at least two months earlier.

For those who received their second dose of Moderna's vaccine at least six months earlier, ACIP recommended a third shot for those age 65 and over, as well as some individuals at risk or severe illness and those at high risk of exposure to the virus through their jobs.

Dr. Helen Talbot, an infectious disease expert at Vanderbilt University and a panel member, said she voted for the recommendation, but cautioned, "Moderna has very good vaccine efficacy. There will be some confusion with the higher versus lower dose."

Booster doses of the Moderna vaccine will be 50 micrograms, half the strength of the original shots.

"Those not at high risk should be really thoughtful about getting the higher dose. I do think we need to be very aware of potential complications."

Experts said communicating those risks could be an issue, especially given the flexibility of allowing people to choose a different vaccine from their original series.

"At the end of the day, even that phrase 'mix and match' pretty much gives people the latitude to ... do pretty much anything," Glen Nowak, a risk communication professor at the University of Georgia and former communications director for CDC’s National Immunization Program said after the meeting. "I think that's going to be an issue."

The FDA and CDC previously signed off on booster shots of the COVID-19 vaccine from Pfizer Inc (NYSE:PFE) and partner BioNTech SE for the same groups included in the Moderna recommendations.

Pfizer released data on Thursday suggesting that a booster dose was highly protective for those age 16 and older compared with protection nearly a year after receiving the two-dose regimen due to waning efficacy over time.

About 11.6 million people have so far received a booster dose, according to data from the CDC https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-total-admin-rate-total.

The FDA and CDC have been under pressure to authorize the additional shots after the White House announced plans in August for a widespread booster campaign.

Other countries such as Israel have begun offering boosters to a broad population, but it is not yet known whether the United States will follow suit.

U.S. CDC signs off on Moderna, J&J COVID-19 vaccine boosters, mix-and-match shots
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email